

## Sartorius to acquire Alumedix for £415 M

10 August 2022 | News

**The acquisition will strengthen its portfolio of innovative advanced therapy solutions**



The life science group Sartorius, through its French listed subgroup Sartorius Stedim Biotech, has agreed to acquire 100 percent of Alumedix Ltd. from private investors.

The Nottingham, UK-based company provides best-in-class recombinant albumin-based solutions. Recombinant human albumin is an important component for the biopharmaceutical industry required for various applications, for example as an animal-free additive to cell culture media and for the stabilization of vaccines and viral therapies.

The business, founded in 1984, has more than 100 employees and is expected to generate revenue of approximately £33 million in 2022 with a significant double-digit EBITDA margin. The agreed purchase price amounts to approximately £415 million. The transaction is subject to regulatory approval and is expected to close before the end of the third quarter of 2022.

Alumedix will be part of the Bioprocess Solutions Division, and the existing 72,000-square-foot site in Nottingham will be established as a centre of excellence for innovation and GMP-compliant production of critical raw materials.